These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23918156)

  • 41. Cutaneous manifestations of Prader-Willi syndrome.
    Bornhausen-Demarch E; Célem L; Carvalhal R; Souza C; Martins P; Almeida AP; Lupi O
    Cutis; 2012 Sep; 90(3):129-31. PubMed ID: 23094311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Extreme obesity in Prader-Willi Syndrome (PWS)].
    Damiano J; Ficko C; Garrabé E; Mayaudon H; Dupuy O; Carmoi T; Bordier L; Bauduceau B
    Rev Med Interne; 2003 Sep; 24(9):617-20. PubMed ID: 12951183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prader-Willi syndrome].
    Sarda P
    Soins Pediatr Pueric; 2013; (274):20-3. PubMed ID: 24228330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EFFECT OF GROWTH HORMONE THERAPY IN CHILDREN WITH PRADER-WILLI SYNDROME - OUR FIRST EXPERIENCES.
    Stipančić G; Požgaj Šepec M; La Grasta Sabolić L
    Acta Clin Croat; 2018 Dec; 57(4):744-755. PubMed ID: 31168212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GH treatment reduces total ghrelin in Prader-Willi syndrome (PWS) and may confound ghrelin studies in young PWS children.
    Hauffa BP; Petersenn S
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):155-6. PubMed ID: 19178506
    [No Abstract]   [Full Text] [Related]  

  • 46. Sexual dichotomy of gonadal function in Prader-Willi syndrome from early infancy through the fourth decade.
    Hirsch HJ; Eldar-Geva T; Bennaroch F; Pollak Y; Gross-Tsur V
    Hum Reprod; 2015 Nov; 30(11):2587-96. PubMed ID: 26345685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome.
    Böhm B; Ritzén EM; Lindgren AC
    Acta Paediatr; 2015 Jan; 104(1):59-67. PubMed ID: 25263744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth hormone therapy, muscle thickness, and motor development in Prader-Willi syndrome: an RCT.
    Reus L; Pillen S; Pelzer BJ; van Alfen-van der Velden JA; Hokken-Koelega AC; Zwarts M; Otten BJ; Nijhuis-van der Sanden MW
    Pediatrics; 2014 Dec; 134(6):e1619-27. PubMed ID: 25422026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome.
    Dykens EM; Roof E; Hunt-Hawkins H
    J Child Psychol Psychiatry; 2017 Jan; 58(1):64-74. PubMed ID: 27481444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
    Eiholzer U; l'Allemand D; van der Sluis I; Steinert H; Gasser T; Ellis K
    Horm Res; 2000; 53(4):200-6. PubMed ID: 11044804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome.
    Sipilä I; Sintonen H; Hietanen H; Apajasalo M; Alanne S; Viita AM; Leinonen E
    Acta Paediatr; 2010 Nov; 99(11):1712-8. PubMed ID: 20545932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome.
    McCarthy JM; McCann-Crosby BM; Rech ME; Yin J; Chen CA; Ali MA; Nguyen HN; Miller JL; Schaaf CP
    J Med Genet; 2018 May; 55(5):307-315. PubMed ID: 29496979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small mosaic deletion encompassing the snoRNAs and SNURF-SNRPN results in an atypical Prader-Willi syndrome phenotype.
    Anderlid BM; Lundin J; Malmgren H; Lehtihet M; Nordgren A
    Am J Med Genet A; 2014 Feb; 164A(2):425-31. PubMed ID: 24311433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth charts for Thai children with Prader-Willi syndrome aged 0-18 years.
    Mongkollarp N; Tim-Aroon T; Okascharoen C; Wichajarn K; Phosuwattanakul J; Chongviriyaphan N; Wattanasirichaigoon D
    Orphanet J Rare Dis; 2020 May; 15(1):111. PubMed ID: 32375863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial.
    Reus L; Pelzer BJ; Otten BJ; Siemensma EP; van Alfen-van der Velden JA; Festen DA; Hokken-Koelega AC; Nijhuis-van der Sanden MW
    Res Dev Disabil; 2013 Oct; 34(10):3092-103. PubMed ID: 23886754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.
    Miller JL; Shuster J; Theriaque D; Driscoll DJ; Wagner M
    J Clin Sleep Med; 2009 Oct; 5(5):448-53. PubMed ID: 19961030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nutrient intake and body composition variables in Prader-Willi syndrome--effect of growth hormone supplementation and genetic subtype.
    Galassetti P; Saetrum Opgaard O; Cassidy SB; Pontello A
    J Pediatr Endocrinol Metab; 2007 Apr; 20(4):491-500. PubMed ID: 17550213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome.
    l'Allemand D; Eiholzer U; Schlumpf M; Steinert H; Riesen W
    Eur J Pediatr; 2000 Nov; 159(11):835-42. PubMed ID: 11079197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.